

Kojic acid-derived tyrosinase inhibitors: synthesis and bioactivity

Seyedeh Mahdiah Hashemi, Saeed Emami*

Department of Medicinal Chemistry, Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran

Received: Dec 14, 2014, Revised: Jan 11, 2015, Accepted: Jan 18, 2015

Abstract

Tyrosinase is a key enzyme for melanin biosynthesis, catalyzing the oxidation of L-tyrosine to L-dopaquinone. The tyrosinase inhibition is an effective approach to control hyperpigmentation in human skin and enzymatic browning in fruits and vegetables. Kojic acid is a naturally-occurring tyrosinase inhibitor which has been clinically used to treat the hyperpigmentation of skin. However, kojic acid as a hydrophilic small-molecule has insufficient inhibitory activity and stability, with considerable toxicity. To overcome these drawbacks, synthetic derivatives of kojic acid were developed, which exhibited enhanced tyrosinase inhibitory activity and more favorable stability relative to kojic acid. In this context, the synthesis and biological activity of kojic acid derivatives as tyrosinase inhibitors have been highlighted.

Keywords: Kojic acid, 4H-pyran-4-one derivatives, enzyme inhibitors, structural modifications

Pharm Biomed Res 2015; 1(1): 1-17

DOI: 10.18869/acadpub.pbr.1.1.1

Introduction

Melanin is a dark pigment produced by about 10% of skin cells in the innermost layer of the epidermis (1). This compound is a heteropolymer of indole derivatives and is produced inside melanosomes through a series of oxidative reactions involving the amino acid tyrosine in the presence of the enzyme tyrosinase (Fig. 1). The type and amount of produced melanin in the melanosomes generates the actual color of the skin (2). Melanogenesis is a physiological process, which plays an important role in the prevention of sun-induced skin injury. Although the melanin production in

human skin is a major defense mechanism against ultraviolet (UV) light, the accumulation of an excess of epidermal pigments can cause various hyperpigmentation disorders, such as melasma, age spots, and sites of actinic damage (3).

Tyrosinase (EC 1.14.18.1), also known as polyphenoloxidase (PPO), is a copper-containing bifunctional enzyme with a molecular weight of approximately 60–70 kDa in mammals and is found exclusively in melanocytes (1,4). It catalyzes two distinct reactions of melanin synthesis (Fig. 1); the hydroxylation of




Figure 1 The role of tyrosinase enzyme in the melanogenesis process

L-tyrosine to form 3,4-dihydroxyphenylalanine (L-DOPA) by monophenolase action and the oxidation of L-DOPA to the corresponding *o*-dopaquinone by diphenolase activity (5). Dopaquinone is highly reactive and can polymerize spontaneously to form melanin in a series of reaction pathways (6). The tyrosinase can be considered as a rate-limiting enzyme in the melanin biosynthesis (7). Accordingly, tyrosinase inhibitors significantly reduce pigmentation in melanosomes and avoid excessive melanogenesis. Some tyrosinase inhibitors have useful application in cosmetics and pharmaceutical products for the prevention of the overproduction of melanin in the epidermis (8). On the other hand, melanogenesis affects the color quality and flavor of foods. The enzymatic action of tyrosinase causes the browning in fruits and vegetables. Thus, tyrosinase enzyme plays an important role in loss of nutritional and market values of foods. In the food industry, tyrosinase inhibitors, especially from natural sources have great potential in controlling the quality and economics of fruits and vegetables (9). Many efforts have been spent in the search for effective and safe tyrosinase inhibitors, and a large number of naturally occurring and synthetic tyrosinase inhibitors were extensively reported (10-12). However, only few of them are practically applicable due to their weak intrinsic activities or safety concerns. Therefore, it is still necessary to search and develop novel tyrosinase inhibitors with potent activity and lower side effect (4).

Kojic acid

Kojic acid (5-hydroxy-2-(hydroxymethyl)-4H-pyran-4-one, **1**) (Fig. 2) is one of the metabolites




Figure 2 The structure of kojic acid

produced by various fungal or bacterial strains such as aspergillus and penicillium and has been used in many countries as a skin-whitening agent because of its tyrosinase inhibitory activity on melanin synthesis. The biological activities of kojic acid are attributed to its γ -pyranone structure that contains an enolic hydroxyl group. If the enolic hydroxyl group is protected, its tyrosinase inhibitory activity is completely lost. It acts by chelating copper at the active site of the tyrosinase enzyme (13). Melanocytes that are treated with kojic acid become nondendritic and have decreased melanin content (14). Kojic acid was reported to have a high-sensitizing potential and to potentially cause irritant contact dermatitis. However, it is useful in patients who cannot tolerate hydroquinone and it may be combined with a topical corticosteroid to reduce irritation (15). Additionally, it also acts as an antioxidant and scavenges reactive oxygen species that are released excessively from cells or generated in tissue or blood (16). The reaction of kojic acid with metal salts of aluminium, chromium, cobalt, copper, gold, indium, iron, nickel, manganese, palladium, vanadium, and zinc results in the formation of stable metal kojate complexes (17-20). Due to its iron chelating activity, kojic acid and its derivatives play an important role in the management of iron-overload diseases such as β -thalassemia or anemia (21-25). Moreover, various biological effects including antibacterial (26, 27), antifungal (28, 29), antiviral (30), anti-inflammatory (31), antineoplastic (32-34), pesticide (35), radioprotective (20), antidiabetic (36), and anticovulsant (37, 38) activities have been reported for kojic acid and its derivatives.

Kojic acid derivatives as tyrosinase inhibitors

Kojic acid is a naturally-occurring tyrosinase inhibitor, which has been clinically used to treat the hyperpigmentation of skin. However, kojic acid has insufficient inhibitory activity and stability, with considerable toxicity. To overcome these drawbacks, synthetic derivatives of kojic acid were developed. We discuss here the major modifications

which were made on the kojic acid structure.

Conversion of γ -pyranone to 4-pyridinone: O-1 modification

The replacement of oxygen in the γ -pyranone ring with nitrogen resulted in 4-pyridinone analogs of kojic acid (Fig. 3).




Figure 3 O-1 modification in kojic acid

Accordingly, a series of hydroxypyridinone-L-phenylalanine conjugates **5** (Fig. 4), starting from kojic acid was synthesized by Li et. al. and evaluated against mushroom tyrosinase (39). It was found that compound containing 1-octyl moiety ($R = n\text{-C}_8\text{H}_{17}$) had potent inhibitory effect against mushroom tyrosinase. MTT assay indicated that this compound was non-toxic to tested cell lines. For the synthesis of compounds, firstly kojic acid (**1**) was O-benzylated by benzyl chloride, and then reacted with an appropriate alkylamine to give compound **3**. The alcoholic compound **3** was conjugated with N-protected L-phenylalanine by using EDC and DMAP.




Figure 4 Synthesis of hydroxypyridinone-L-phenylalanine conjugates **5**

Finally, N-deprotection was carried out by hydrogenation at 30 psi H_2 for 5–6 h at room temperature to give target compounds **5** (39).

Saghaie et al. synthesized a series of 3-hydroxy-4-pyridinones **9** starting from kojic acid in high yield (Fig. 5), and evaluated them for their inhibitory activity toward tyrosinase enzyme using dopachrome method (40). As illustrated in Fig. 5, the amine insertion in the O-benzyl kojic acid (**2**) resulted in compound **6**, which subsequently oxidized to aldehyde **7**. Condensation of aldehyde **7** with aniline derivatives gave Schiff base **8**. Reduction of C=N bond and O-debenzylolation in compound **8** by using Pd/C hydrogenation afforded final compounds **9**. Their biological results show that all synthesized compounds have inhibitory effect on tyrosinase activity. Among compounds studied those containing two free hydroxyl group were more potent than their analogues with one hydroxyl group. Also, substitution of a methyl group on position N_1 of the hydroxypyridinone ring seems to confer more inhibitory potency (40).

Esterification of 2-(hydroxymethyl) group of kojic acid

The primary alcoholic group of kojic acid can be esterified with different acids. However, the convenient method for preparation of kojic esters is via chloro-kojic acid (**10**) and subsequent nucleophilic substitution with a suitable carboxylate salt (Fig. 6).

Nitric oxide (NO) is an important inflammatory mediator, synthesized by inducible nitric oxide synthase (iNOS).




Figure 5 Synthesis of 3-hydroxy-4-pyridinones **9**




Figure 6 The convenient method for preparation of kojic esters **11**

Overproduction of NO can lead to inflammatory diseases (41). Thus, much effort has been focused on finding potent inhibitors of NO production. However, there have been few studies on the use of kojic acid and its derivatives as NO inhibitors. Recently, a series of kojic acid derivatives **12** containing ester linkage, and kojic-benzoates **16** containing adamantane moiety were synthesized and evaluated their inhibitory activities against tyrosinase and NO production. As depicted in Fig. 6, the reaction of kojic acid with thionyl chloride produces compound **10**,

which is conveniently *O*-methylated to give compound **13** using dimethylsulfate and potassium carbonate in acetone under reflux conditions. Chlorides **10** and **13** react with potassium salts of benzoic acids or of cinnamic acids in DMF at 110–120 °C to give the corresponding ester derivatives **12** (Fig. 7). Adamantylbenzoic acids **15** were synthesized by reacting benzoic acids with 1-adamantanol in trifluoroacetic acid (TFA) under reflux conditions. Adamantylbenzoic acids **15** reacted with potassium hydroxide in methanol to afford the potassium salts. After methanol removal, the potassium salts react with

corresponding ester derivatives **16** (Fig. 8) (42). The obtained biological results revealed that 3,4-methylenedioxy cinnamic acid ester of kojic acid (**12c**) exhibited more potent inhibitory effect on tyrosinase than kojic acid. The structure of compound **12c** (Fig. 9) comprises two main parts: a

chelating part of kojic acid and a hydrophobic part of cinnamic acid. However, the hydroxybenzoate derivatives of kojic acid containing the adamantyl moiety showed no inhibitory activity. The reason for no inhibition may be either steric hindrance of the adamantyl moiety or insufficient copper chelating tendency




Figure 7 Synthesis of kojic esters **12a-e**




Figure 8 Synthesis of kojic-benzoate esters **16** containing adamantyl moiety

more potent depigmenting activity ($IC_{50} = 23.51 \mu\text{M}$) than compound **12c** ($IC_{50} > 100 \mu\text{M}$) which is the parent compound of the side product. However, it has no tyrosinase inhibitory activity (44).

A novel kojic acid derivative containing trolox (**21**), namely (\pm)-5-hydroxy-4-oxo-4*H*-pyran-2-yl-methyl 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylate (**22a**, Fig. 12), was synthesized (45). Indeed, the two biologically active compounds, kojic acid and trolox, were conjugated via an ester bond as they are expected to have dual action. The antioxidant activity and the tyrosinase inhibitory activity of kojic acid derivative **22a** on melanogenesis were evaluated. Compound **22a** exhibited potent tyrosinase inhibitory activity and radical

scavenging activity. Limited structure–activity relationship (SAR) investigations indicated that the tyrosinase inhibitory activity may originate from the kojic acid moiety, and the radical scavenging activity may be due to the phenolic hydroxyl group of trolox. Compound **22a** also exhibited potent depigmenting activity in a cell-based assay. The limited SAR investigations revealed that the depigmenting activity of **22a** may be due to the synergistic activities of kojic acid and its trolox moiety (45). As presented in Fig. 13, kojyl chloride derivatives **10** or **13** reacted with potassium salts of trolox, 4-hydroxybenzoic acid or 6-hydroxynaphthoic acid in DMF at 110–120 °C to give the corresponding ester derivatives **22a–d** (45).




Figure 12 Structures of antioxidant compound trolox (**21**) and kojic acid-trolox conjugate (**22a**)




Figure 13 Synthesis of kojic acid-trolox conjugate and related compounds

Kojic acid derivatives conjugated with amino acids

In a report by Noh et al. (46), kojic acid has been coupled with amino acids to obtain kojic acid–amino acid amide conjugates **24** as new stable tyrosinase inhibitors (Fig. 14). Firstly, the primary alcohol of kojic acid was reacted with 1,1'-carbonyldiimidazole (CDI) and then coupled to the resin-bounded amino acids. In this reaction, the kojyl moiety is connected to the amino acid via a carbamate linker. After cleavage of the kojic acid–amino acid amide (**24**, KA-AA-NH₂) from the resin, it was characterized by MALDI-TOF mass spectroscopy. The conjugates of different amino acid amides with kojic acid were evaluated for their inhibitory activity on mushroom tyrosinase. The results showed that most of conjugates had better inhibitory activity than the parent molecule kojic acid. When amino acids such as phenylalanine, tryptophan, tyrosine, and histidine, which possess aromatic side chains, were conjugated to kojic acid, the

tyrosinase inhibitory activity was enhanced dramatically. Noh et al. suggested that the aromatic residue of mentioned amino acids may contribute to the binding of the inhibitor to the hydrophobic pocket of the enzyme. Further studies showed that kojic acid–phenylalanine amide conjugate (**24a**, KA-F-NH₂, Fig. 15) showed the strongest inhibitory activity, which was maintained for over 3 months at 50 °C, and acted as a noncompetitive inhibitor (46).

Kim group synthesized a series of kojic acid-tripeptides by solid-phase parallel synthesis and evaluated them as tyrosinase inhibitors (47). As depicted in Fig 16, the resin-bound tripeptides reacted with activated kojic acid **23**. After cleavage, the kojic acid-tripeptide conjugates **26** were obtained in good yields. Most of the kojic acid-tripeptide conjugates exhibited more potent tyrosinase inhibitory activities than kojic acid. The most potent compound (kojic acid-FWY) was about 100-fold more potent than kojic acid. Furthermore, it was less toxic than kojic acid and its storage




Figure 14 Synthesis of kojic acid–amino acid amide conjugates (**24**, KA-AA-NH₂)




Figure 15 Structure of kojic acid–phenylalanine amide conjugate (**24a**)




Figure 16 Solid-phase synthesis of kojic acid-tripeptides 26

stabilities was approximately 15-times higher than that of kojic acid. In addition, this research group demonstrated that kojic acid-tripeptide amides have similar tyrosinase inhibitory relative to kojic acid-tripeptide free acids, while exhibit more favorable storage stability. These findings indicate the importance of C-terminal amide form in kojic acid-peptide conjugates.

Compounds containing two molecules of kojic acid

In a study by Kobayashi et al., various amino acid derivatives of kojic acid (28, Fig 17) were synthesized to improve the

tyrosinase inhibitory activity of kojic acid (48). The *N*-kojic-amino acid 27 were synthesized starting from kojic acid and appropriate amino acid by using DSC (*N,N'*-disuccinimidylcarbonate) and DMAP (4-dimethylaminopyridine). Subsequent esterification of another molecule of kojic acid with compound 27 gave the target compounds 28. Almost all synthesized compounds were more active than kojic acid. In general, *N*-kojic-amino acid-kojiate 28 was found to have a higher inhibitory activity than *N*-kojic-amino acid 27. Among them, the *N*-kojic-*L*-phenylalanylkojiate was the most potent compound. It was 380 times more potent




Figure 17 Synthesis of *N*-kojic-amino acid-kojiate (28)

than kojic acid. The inhibition mechanism of these derivatives is considered to be non-competitive which is similar to that of kojic acid (48). In another study, two molecules of kojic acid were connected by various linkers containing chemical bonds such as ester, amide and thioether (Fig. 18) (49). Chlorokojic acid (**10**) was reacted with sodium azide in DMF and subsequently converted to kojyl amine HBr **29**. The coupling of compound **29** with succinyl chloride in the presence of triethylamine in THF afforded di-kojylsuccinic amide **30**. The nucleophilic substitution of chlorokojic acid (**10**) with potassium salt of kojyl succinic acid gave di-kojylsuccinate **31**. The reaction of compound **10** with dithiols in the presence of TEA afforded thioethers **32** (Fig. 18). The synthesized dimmers of kojic acid (**30-32**) were evaluated against tyrosinase enzyme and melanin formation in melan-a melanocytes. Among them, dithioether derivatives (**32a-c**) showed the highest inhibitory activity. The obtained results showed that the dithioether linker and its flexibility are important for improving anti-

melanogenic activity. The propylene thioether compound **32b** with IC₅₀ value of 1.97 μM was the most active inhibitor against tyrosinase enzyme. It was about 25-fold more potent than kojic acid. In melan-a cell based assay, butylene dithioether derivative **32c** exhibited superior inhibitory activity of melanin synthesis, being approximately 1000 times more potent than kojic acid (49). Moreover, compound **32b** exhibited the most potent inhibitory activity of NO production in LPS activated macrophages (50).

Rho et al. further investigated the structure-activity relationship of kojic acid thioethers by preparing mono-kojyl thioethers **33**, sulfoxides **34**, and sulfones **35** (Fig. 19) (51). Kojyl thioethers **33** were prepared by the reaction of kojyl chloride **10** with potassium salts of thiols. Mono-oxidation of the thioethers **33** with MCPBA (*m*-chloroperbenzoic acid) in CH₂Cl₂ produced sulfoxide derivatives **34**. The treatment of thioether derivatives **33** with oxone in a mixture of MeOH/H₂O afforded sulfone derivatives **35**. In the tyrosinase inhibition bioassay, the




Figure 18 Synthesis of kojic acid dimmers 30-32




Figure 19 Synthesis of mono-kojyl thioethers **33**, sulfoxides **34**, and sulfones **35**

pentyl, hexyl, and cyclohexyl thioethers exhibited potent inhibitory activity. In contrast, sulfoxide and sulfone derivatives **34** and **35** showed decreased activity. The pentyl thioether derivative with IC_{50} value of $0.097 \mu\text{M}$ was the most potent compound against tyrosinase. The obtained

results for inhibitory activity of NO production were similar to those of tyrosinase inhibition. Stilbene-like kojic acid derivative **42** was synthesized by joining two pyrone rings through an ethylene linkage by Horner-Emmons reaction of the protected aldehyde **37** with phosphonate **40** (Fig. 20). Both




Figure 20 Synthesis of stilbene-like kojic acid derivative **42**

intermediates **37** and **40** were derived from kojic acid as depicted in Fig. 20. The enzymatic assay revealed that the tyrosinase inhibitory activity of compound **42** was about 8 times more potent than that of kojic acid. This compound also exhibited significant melanin synthesis inhibitory activity in cell-based assay. The obtained results for dimeric compound **42** compared to kojic acid indicate that the connection of two pyrone rings of kojic acid through a suitable linker can be an useful strategy for finding new potent tyrosinase inhibitors (3).

C-2 Side chain-modified kojic acid derivatives

Chemically, the 2-(hydroxymethyl) side chain in the kojic acid structure is a good site for oxidation to related aldehyde. With a key intermediate aldehyde in hand, diverse derivatives can be prepared. As shown in Fig. 20, for oxidation of primary alcohol in kojic acid structure, the enolic OH should be protected with a suitable group such as *p*-methoxybenzyl. The oxidation of protected kojic acid **36** with MnO₂ resulted in protected aldehyde **37**. Kang et al. used this intermediate for synthesis of pyronyl-acrylic acid esters **44**, which share structural features of kojic acid and hydroxylated cinnamic acid (caffeic acid, **43**, Fig. 21) (52).

Horner-Emmons condensation of aldehyde **37** with compound **45** gave methyl ester **46**, which hydrolyzed with LiOH in aqueous THF to afford acid **47**. Compound **47** was *O*-alkylated with appropriate alkyl iodides or alkyl tosylates. The target compounds **44** were obtained by removing of the PMB-protecting group using trifluoroacetic acid (TFA) in CH₂Cl₂ (Fig. 22).

The abilities of synthesized compound **44** to inhibit tyrosinase and melanin production were evaluated by Kang et al. Among the tested derivatives, compounds derived from diethylene glycol were found to inhibit melanin production at 20 µg/ml. It should be noted that in this test, kojic acid inhibited melanin production at 200 µg/ml (52).

Yi et al. have synthesized thiosemicarbazone analogs of kojic acid (**52**) as tyrosinase inhibitors (53). The synthesis of the target compounds **52a,b** was outlined in Fig. 23. Firstly *O*-methyl kojic acid (**49**) was oxidized to aldehyde **50** by using MnO₂. The *O*-methyl group was removed by AlCl₃ to give compound **51**. The condensation reaction of carboxaldehydes **50** or **51** with the thiosemicarbazide in anhydrous ethanol in the presence of acetic acid afforded corresponding thiosemicarbazone analogs **52**. The inhibitory evaluation of




Figure 21 Design of hybrid compounds pyronyl-acrylic acid esters **44**




Figure 22 Synthesis of hybrid compounds pyronyl-acrylic acid esters 44

compounds **52a,b** against commercial mushroom tyrosinase revealed that *O*-methylated compound **52a** showed no inhibitory activity, while thiosemicarbazone analog **52b** bearing a free enolic group exhibited high activity against mushroom tyrosinase (IC₅₀ = 11 μM). The latter compound was about 9-fold more potent than the parent compound kojic acid (53).

Miscellaneous derivatives

The topical formulations of kojic acid are used as skin-lightening agent. However, it is hardly absorbed through the lipid membrane of its target sites, the melanocytes due to its hydrophilic character (54). In some investigations, it has been attempted to connect the kojic acid to a suitable carrier.

Kim et al. synthesized a kojic acid analog




Figure 23 Synthetic pathway to thiosemicarbazone analogs of kojic acid (52)

(kojyl-APPA, **56**) containing 5-[(3-aminopropyl)phosphinoxy]- moiety as stable derivative of kojic acid. Compound **56** was prepared by the reaction of kojic acid with 2-chloro-[1,3,2] oxazaphosphinane 2-oxide (**54**) in the presence of TEA in $\text{CHCl}_3/\text{EtOH}$, followed by hydrolysis in acidic medium of $\text{H}_2\text{O}/\text{MeOH}$ (Fig. 24). Interestingly, the alcoholic OH group of kojic acid did not take part in reaction with compound **54**. The effects of compound **56** on tyrosinase activity and melanin synthesis were evaluated by Kim and co-workers. The masked form of kojic acid **56** displayed higher stability than kojic acid. Also, its permeation through the skin was about 8-times more than kojic acid. Compound **54** showed no tyrosinase inhibition effect compared with kojic acid *in vitro*, however displayed the same inhibitory effect as kojic acid on melanin synthesis in mouse melanoma and normal human melanocytes.

It seems that compound **56** is converted to kojic acid in living cells (**55**). In another study, Manosroi and co-workers have investigated the entrapment of kojic acid and its oleate ester. Kojic oleate (**57**) was prepared starting from kojic acid and oleic acid in CH_2Cl_2 by using DCC (*N,N*-dicyclohexylcarbodiimide) and DMAP (4-(*N,N*-dimethylamino)pyridine) (Fig. 25). In this study, the entrapment efficiencies of kojic acid and kojic oleate in the vesicles were investigated by dialysis and column chromatography, respectively. The obtained results indicated that kojic oleate could be intercalated in the bilayer structure of the vesicles composed of amphiphile (Span 60, Tween 61 or DPPC)/cholesterol/dicetyl phosphate at molar ratio of 9.5:9.5:1.0. In general, they concluded that the esterification of kojic acid improved its entrapment in the vesicles (**56**).




Figure 24 Synthesis of 5-[(3-aminopropyl)phosphinoxy]-kojic acid (**56**)




Figure 25 Synthesis of kojic oleate (**57**)

Conclusion

Kojic acid is a small-molecule with tyrosinase inhibitory activity, which has been used as a skin-lightening agent. This agent is the most intensively studied inhibitor of tyrosinase; however it has unsatisfactory inhibitory activity, insufficient stability and unwanted side effects. To overcome these disadvantages, researchers have attempted to design new analogs of kojic acid with higher potency, satisfactory stability and safety. Diverse modifications on this small-molecule have

been made to find new tyrosinase inhibitors. The main modifications were conversion of the γ -pyranone to 4-pyridinone, esterification of 2-(hydroxymethyl) group, C-2 side chain-modification, and conjugation of kojic acid with amino acids.

Conflict of interest statement

The authors claim that they have no conflicting interest in this study.

References

1. Parvez Sh, Kang M, Chung HS, Cho C, Hong MC, Shin MK, Bae H. Survey and mechanism of skin depigmenting and lightening agents. *Phytother Res* 2006;20:921–34.
2. Shi YL, Benzie IFF, Buswell JA. Role of tyrosinase in the genoprotective effect of the edible mushroom *Agaricus bisporus*. *Life Sci* 2002;70:1595–1608.
3. Lee YS, Park JH, Kim MH, Seo SH, Kim HJ. Synthesis of tyrosinase inhibitory kojic acid derivative. *Arch Pharm Chem Life Sci* 2006;339:111–4.
4. Yan Q, Cao R, Yi W, Chen Z, Wen H, Ma L, Song H. Inhibitory effects of 5-benzylidene barbiturate derivatives on mushroom tyrosinase and their antibacterial activities. *Eur J Med Chem* 2009;44:4235–43.
5. Sánchez-Ferrer A, Rodríguez-López JN, García-Cánovas F, García-Garmona F. Tyrosinase: a comprehensive review of its mechanism. *Biochim Biophys Acta* 1995;1247:1–11.
6. Seo SY, Sharma VK, Sharma N. Mushroom tyrosinase: recent prospects. *J Agric Food Chem* 2003;51:2837–53.
7. Masuda T, Yamashita D, Takeda Y, Yonemori S. Screening for tyrosinase inhibitors among extracts of seashore plants and identification of potent inhibitors from *Garcinia subelliptica*. *Biosci Biotechnol Biochem* 2005;69:197–201.
8. Solano F, Briganti S, Picardo M, Ghanem G. Hypopigmenting agents: an updated review on biological, chemical and clinical aspects. *Pigment Cell Res* 2006;19:550–71.
9. Kim YJ, Uyama H. Tyrosinase inhibitors from natural and synthetic sources: structure, inhibition mechanism and perspective for the future. *Cell Mol Life Sci* 2005;62:1707–23.
10. Nihei K, Yamagiwa Y, Kamikawa T, Kubo I. 2-Hydroxy-4-isopropylbenzaldehyde, a potent partial tyrosinase inhibitor. *Bioorg Med Chem Lett* 2004;14:681–83.
11. Yi W, Cao R, Peng W, Wen H, Yan Q, Zhou B, Ma L, Song H. Synthesis and biological evaluation of novel 4-hydroxybenzaldehyde derivatives as tyrosinase inhibitors. *Eur J Med Chem* 2010;45:639–46.
12. Lam KW, Syahida A, UI-Haq Z, Rahman MBA, Lajis NH. Synthesis and biological activity of oxadiazole and triazolothiadiazole derivatives as tyrosinase inhibitors. *Bioorg Med Chem Lett* 2010;20:3755–9.
13. Burdock GA, Soni MG, Carabin IG. Evaluation of health aspects of kojic acid in food. *Regulatory Toxicol Pharmacol* 2001;33:80–101.
14. Moon KY, Ahn KS, Lee J, Kim YS. Kojic acid, a potential inhibitor of NF-kappa B activation in transfectant human HaCaT and SCC-13 cells. *Arch Pharm Res* 2001;24:307–11.
15. Piamphongsant T. Treatment of melasma: a review with personal experience. *Int J Dermatol* 1998;37:897–903.
16. Cabanes J, Chazarra S, Garcia-Carmona F. Kojic acid, a cosmetic skin whitening agent, is a slow-binding inhibitor of catecholase activity of tyrosinase. *J Pharm Pharmacol* 1994;46:982–5.
17. Hryniewicz K, Stadnicka K, Pattek-Janczyk A. Crystal structure and vibrational spectra of 2-chloromethyl-5-hydroxy-4H-pyran-4-one as potential ligands for Fe(III) complexes. *J Mol Struct* 2009;919:255–70.
18. Zaremba K, Lasocha W, Adamski A, Stanek J, Pattek-Janczyk A. Crystal structure and magnetic properties of tris(2-hydroxymethyl-4-oxo-4H-pyran-5-olato κ O5, O4)iron(III). *J Coord Chem* 2007;60:1537–46.
19. Yang CT, Sreerama SG, Hsieh WY, Liu S. Synthesis and characterisation of a novel macrocyclic chelator with 3-hydroxy-4-pyrone chelating arms and its complexes with medically important metals. *Inorg Chem* 2008;47:2719–27.
20. Emami S, Hosseinimehr SJ, Taghdisi SM, Akhlaghpour S. Kojic acid and its manganese and zinc complexes as potential radioprotective agents. *Bioorg Med Chem Lett* 2007;17:45–8.

21. Moggia F, Brisset H, Fages F, Chaix C, Mandrand B, Dias M, Levillain E. Design, synthesis and redox properties of two ferrocene-containing iron chelators. *Tetrahedron Lett* 2006;47:3371–74.
22. Stenson AC, Cioffi EA. Speciation of M+3-hydroxypyrrone chelation complexes by electrospray ionization ion trap and Fourier transform ion cyclotron resonance mass spectrometry. *Rapid Commun Mass Spectrom* 2007;21:2594–2600.
23. Brtko J, Rondahl L, Fickova M, Hudecova D, Eybl V, Uher M. Kojic acid and its derivatives: history and present state of art. *Cent Eur J Publ Health* 2004;12:16–18.
24. Sudhir PR, Wu HF, Zhou ZC. Probing the interaction of kojic acid antibiotics with iron(III) chloride by using electrospray tandem mass spectrometry. *Rapid Commun Mass Spectrom* 2005;19:209–12.
25. Zborowski K, Grybos R, Proniewicz L M. Molecular structure of oxovanadium (IV) complexes with maltol and kojic acid: a quantum mechanical study. *Inorg Chem Commun* 2005;8:76–8.
26. Emami S, Ghafouri E, Faramarzi MA, Samadi N, Irannejad H, Foroumadi A. Mannich bases of 7-piperazinylquinolones and kojic acid derivatives: synthesis, in vitro antibacterial activity and in silico study. *Eur J Med Chem* 2013;68:185–191.
27. Aytemir MD, Hider RC, Erol DD, Özalp M, Ekizoğlu M. Synthesis of new antimicrobial agents; amide derivatives of pyranones and pyridinones. *Turk J Chem* 2003;4:445–52.
28. Melník M, Uher M, Brtko J, Mrozińska D, Mroziński J. Cooper(II) kojates and their antifungal effects. *Polish J Chem* 1993;67:1219–25.
29. Hudecová D, Uher M, Brtko J. Halogen derivatives of kojic acid with antifungal effects. *Biologia* 1992;47:483–8.
30. Aytemir MD, Özçelik B. A study of cytotoxicity of novel chlorokojic acid derivatives with their antimicrobial and antiviral activities. *Eur J Med Chem* 2010;45:4089–95.
31. Kojic acid as an anti-inflammatory and analgesic agent. *Japan Kokai Tokkyo Koho JP 80154916*, 1980.
32. Bransová J, Brtko J, Uher M, Novotný L. Antileukemic activity of 4-pyranone derivatives. *Int J Biochem Cell Biol* 1995;27:701–6.
33. Bransová J, Uher M, Brtko J. Regulation of selected biological processes in neoplastic cell lines by halogen derivatives of 5-hydroxy-2-hydroxymethyl-4-pyranone. *Anticancer Res* 1998;18:4423–8.
34. Fickova M, Pravdova E, Rondahl L, Uher M, Brtko J. *In vitro* antiproliferative and cytotoxic activities of novel kojic acid derivatives: 5-benzyloxy-2-selenocyanotomethyl- and 5-methoxy-2-selenocyanotomethyl-4-pyranone. *J App Toxicol* 2008;28:554–9.
35. Uher M, Konečný V, Rajniaková O. Synthesis of 5-hydroxy-2-hydroxymethyl-4H-pyran-4-one derivatives with pesticide activity. *Chem Papers* 1994;48:282–4.
36. Xiong X, Pirrung MC. Modular synthesis of candidate indole-based insulin mimics by Claisen rearrangement. *Org Lett* 2008;10:1151–4.
37. Aytemir MD, Septioğlu E, Çalış Ü. Synthesis and anticonvulsant activity of new kojic acid derivatives. *Arzneim Forsch Drug Res* 2010;60:22–9.
38. Aytemir MD, Çalış Ü. Anticonvulsant and neurotoxicity evaluation of some novel kojic acids and allomaltol derivatives. *Arch Pharm Med Chem Life Sci* 2010;343:173–81.
39. Li DF, Hu P P, Liu M S, Kong X L, Zhang J C, Hider R C, et al. Design and synthesis of hydroxypyridinone-L-phenylalanine conjugates as potential tyrosinase inhibitors. *J Agric Food Chem* 2013;61:6597–03.
40. Saghaie L, Pourfarzam M, Fassihi A, Sartippour B. Synthesis and tyrosinase inhibitory properties of some novel kojic acid. *Res Pharm Sci* 2013;8:233–42.
41. Brown GC, Bal-Price A. Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria. *Mol Neurobiol* 2003;27:325–55.
42. Rho HS, Goh M, Lee J, Ahn SM, Yeon J, Yoo DS, et al. Ester derivatives of kojic acid and polyphenols containing adamantane moiety with tyrosinase inhibitory and anti-inflammatory properties. *Bull Korean Chem Soc* 2011;32:1411–4.
43. Cho JC, Rho HS, Joo YH, Lee CS, Lee J, Ahn SM, et al. Depigmenting activities of kojic acid derivatives without tyrosinase inhibitory activities. *Bioorg Med Chem Lett* 2012;22:4159–62.
44. Cho JC, Rho HS, Baek HS, Ahn SM, Woob BY, Hong YD, et al. Depigmenting activity of new kojic acid derivative obtained as a side product in the synthesis of cinnamate of kojic acid. *Bioorg Med Chem Lett* 2012;22:2004–7.
45. Ahn SM, Rho HS, Baek HS, Joo YH, Hong YD, Shin SS, et al. Inhibitory activity of novel kojic acid derivative containing trolox moiety on melanogenesis. *Bioorg Med Chem Lett* 2011;21:7466–9.
46. Noh JM, Kwak SY, Seo HS, Seo JH, Kim B-G, LeeYS. Kojic acid-amino acid conjugates as tyrosinase inhibitors. *Bioorg Med Chem Lett* 2009;19:5586–9.
47. Kim H, Choi J, Cho JK, Kim SY, Lee YS. Solid-phase synthesis of kojic acid-tripeptides and their tyrosinase inhibitory activity, storage stability, and toxicity. *Bioorg Med Chem Lett* 2004;14:2843–6.
48. Kobayashi Y, Kayahara H, Tadasa K, Tanaka H. Synthesis of *N*-kojic-amino acid and *N*-kojic-amino acid-kojiate and their tyrosinase inhibitory activity. *Bioorg Med Chem Lett* 1996;6:1303–8.
49. Rho HS, Baek HS, Ahn SM, Kim DH, Chang IS. Synthesis of new anti-melanogenic compounds containing two molecules of koji acid. *Bull Korean Chem Soc* 2008;29:1569–71.
50. Yoo DS, Lee J, Choi SS, Rho HS, Cho DH, Shin WC, Cho JY. A modulatory effect of

- novel kojic acid derivatives on cancer cell proliferation and macrophage activation. *Pharmazie* 2010;65:261–6.
51. Rho HS, Ahn SM, Yoo DS, Kim MK, Cho DH, Cho JY. Kojylthioether derivatives having both tyrosinase inhibitory and anti-inflammatory properties. *Bioorg Med Chem Lett* 2010;20:6569–71.
 52. Kang SS, Kim HJ, Jin C, Lee YS. Synthesis of tyrosinase inhibitory (4-oxo-4*H*-pyran-2-yl)acrylic acid ester derivatives. *Bioorg Med Chem Lett* 2009;19:188–91.
 53. Yi W, Dubois C, Yahiaoui S, Haudecoeur R, Belle C, Song H, et al. Refinement of arylthiosemicarbazone pharmacophore in inhibition of mushroom tyrosinase. *Eur J Med Chem* 2011;46:4330–5.
 54. Curto EV, Kwong C, Hermerdorfer H, Glatt H, Santis C, Virador V, et al. Inhibitors of mammalian melanocyte tyrosinase: in vitro comparisons of alkyl esters of gentisic acid with other putative inhibitors. *Biochem Pharmacol* 1991;57:663–2.
 55. Kim DH, Hwang JS, Baek HS, Kim KJ, Lee BG, Chang I, et al. Development of 5-[(3-aminopropyl)phosphinoxy]-2-(hydroxymethyl)-4*H*-pyran-4-one as a novel whitening agent. *Chem Pharm Bull* 2003;51:113–6.
 56. Manosroi A, Wongtrakul P, Manosroi J, Midorikawa U, Hanyu Y, Yuasa M, et al. The entrapment of kojic oleate in bilayer vesicles. *Int J Pharm* 2005;298:13–25.